(NVRO) Nevro - Ratings and Ratios

Nevro Corp (NYSE:NVRO), a leader in neuromodulation technology, specializes in innovative solutions for chronic pain management. The companys flagship HFX spinal cord stimulation (SCS) platform delivers 10 kHz therapy without paresthesia, addressing chronic back and leg pain. Its product portfolio includes the Senza SCS implantable pulse generator (IPG) system, Senza II, Senza Omnia, and the advanced HFX iQ platform, which integrates implantable pulse generators, trial stimulators, and patient remote controls. Nevro also offers sacroiliac joint fusion devices under the NevroV1, NevroFix, and NevroPro brands, along with surgical and percutaneous leads. The company distributes its products through a direct sales force and a network of agents and independent distributors.

Founded in 2006 and headquartered in Redwood City, California, Nevro has established itself as a key player in the medical device industry, focusing on minimally invasive treatments for chronic pain. Its commitment to innovation and evidence-based solutions has positioned it as a pioneer in the field of neuromodulation. For more information, visit their website at https://nevro.com.

3-Month Forecast (Based on Technical and Fundamental Data): - Technical Outlook: NVRO is currently trading below its 200-day SMA ($6.24) but above its 20-day ($5.59) and 50-day ($4.73) SMAs, indicating bearish momentum but with potential stabilization. The ATR of $0.23 suggests reduced volatility in the near term. - Fundamental Outlook: With a market cap of $216.91M and a P/B ratio of 0.79, NVRO is undervalued relative to its book value. However, the negative RoE (-25.33) and lack of P/E visibility raise concerns about profitability. The P/S ratio of 0.52 reflects moderate revenue multiples. - Expected Movement: NVRO is likely to remain range-bound between $4.73 and $6.24 in the next 3 months, with potential upside driven by improving fundamentals or downside risk from ongoing losses.